With your own knowledge and the help of the following document:

Document 1 (Title: Chelation Therapy in Heavy Metal Toxicity): British Anti-Lewisite (BAL; 2,3-dimercaptopropanol) represents a historically significant chelating agent with continued relevance in specific heavy metal poisoning scenarios requiring rapid intervention. Toxicological applications primarily involve arsenic compounds, with BAL demonstrating high-affinity binding through its vicinal thiol groups forming stable coordination complexes with trivalent arsenic species. This interaction effectively prevents and reverses arsenic binding to critical sulfhydryl-containing enzymes including pyruvate dehydrogenase and lipoic acid, thereby mitigating the primary mechanisms of arsenic toxicity. Clinical implementation demonstrates particular efficacy in acute inorganic arsenic poisoning, with improved survival rates and reduced neurological sequelae when administered within early toxicity phases. Similar binding mechanisms apply to mercury toxicity management, with BAL forming stable mercury-sulfur complexes allowing enhanced elimination through biliary and renal pathways. The chelator demonstrates particular utility for inorganic mercury compounds and elemental mercury exposures, though with more variable efficacy for organomercurial species including methylmercury. Amphoteric metals including zinc and copper demonstrate minimal affinity for BAL's thiol groups, with chelation therapy generally not indicated for toxicity involving these metals. Similarly, aluminum toxicity management typically employs alternative chelating agents including deferoxamine rather than BAL due to formation constant limitations. Clinical administration considerations include parenteral delivery requirements due to BAL's poor oral bioavailability, significant dose-dependent side effects, and potential redistribution of certain metals into the central nervous system necessitating careful risk-benefit assessment and monitoring during implementation. Contemporary toxicological management increasingly incorporates newer, less toxic chelating agents while reserving BAL for specific scenarios requiring its unique binding properties despite its adverse effect profile.
Document 2 (Title: Pharmacotherapy of Entamoeba histolytica Infections): Amebiasis management requires targeted pharmacological approaches addressing both intestinal and tissue infections through agents with distinctive spectrum and distribution characteristics. Therapeutic approaches typically distinguish between luminal agents effective against intestinal colonization versus tissue amebicides capable of treating invasive disease including hepatic abscesses. Nitroimidazole derivatives represent the cornerstone of tissue amebicide therapy due to their excellent distribution characteristics and direct amebicidal activity in hepatic and other extraintestinal sites. Metronidazole (FLAGYL®) demonstrates excellent tissue penetration and efficacy against invasive amebiasis, achieving therapeutic concentrations in hepatic abscess fluid and other invasive sites. Clinical studies document cure rates exceeding 90% for uncomplicated amebic liver abscess following appropriate metronidazole regimens. Similarly, secnidazole (FLAGENTYL®) provides effective treatment for tissue amebiasis with the advantage of single-dose administration due to its extended half-life compared to other nitroimidazoles. This pharmacokinetic advantage facilitates improved adherence in resource-limited settings while maintaining comparable clinical efficacy. Ornidazole (TIBÉRAL®) represents another effective tissue amebicide within the nitroimidazole class, demonstrating excellent penetration into hepatic tissue and abscess cavities with similar efficacy profiles to other class members. These agents contrast with medications primarily effective against intestinal luminal infection, including paramomycin and diloxanide furoate, which demonstrate poor systemic absorption limiting their utility against tissue invasion. Similarly, antifungal agents including econazole (PEVARYL®) lack amebicidal activity despite activity against certain other parasites, while antihelminthic agents such as flubendazole (FLUVERMAL®) demonstrate no meaningful activity against protozoan pathogens including Entamoeba histolytica. These pharmacological distinctions inform appropriate agent selection for amebiasis, typically requiring nitroimidazole derivatives for tissue invasion followed by luminal agents to prevent recurrence.
Document 3 (Title: Clinical Manifestations of Ethylene Glycol Exposure): Ethylene glycol intoxication presents a distinctive multi-system toxidrome requiring prompt recognition and intervention due to its potentially lethal consequences. Following ingestion, the parent compound undergoes hepatic metabolism generating multiple toxic metabolites with widespread organ impacts. Kidney injury represents a hallmark manifestation, with calcium oxalate crystalluria progressing to acute tubular necrosis and potential renal failure within 24-72 hours post-ingestion. Characteristic neurological involvement occurs in a biphasic pattern, with initial CNS depression followed by delayed cerebral edema, seizures, and potentially irreversible neurological damage mediated through metabolite neurotoxicity. Profound metabolic derangements typically develop as the intoxication progresses, including a severe high-anion-gap metabolic acidosis resulting from glycolic and oxalic acid accumulation. Concurrent electrolyte abnormalities frequently complicate management, particularly hypocalcemia secondary to calcium oxalate formation. Cardiopulmonary manifestations emerge in moderate to severe poisonings, including myocardial depression, conduction disturbances, and in severe cases, circulatory collapse requiring vasopressor support. Multiple case series document QT prolongation and tachyarrhythmias in significant exposures, sometimes necessitating advanced cardiac life support interventions. Comprehensive toxicology references describe additional rare manifestations in severe cases, though notably excluding ototoxicity or permanent hearing alterations, which remain absent from major case registries despite extensive documentation of other system effects. These collective manifestations create a recognizable pattern distinguishing ethylene glycol poisoning from other toxic alcohol ingestions, guiding appropriate diagnostic and therapeutic interventions including fomepizole administration, potential hemodialysis, and supportive care.

Answer the following list question.
Question: The therapeutic administration of British Anti Lewisite (BAL) or 2,3-dimercaptopropanol (DIMERCAPROL®) is recommended in case of poisoning by salts of:
Options:
1. Arsenic
2. Aluminum
3. Mercury
4. Iron
5. Copper

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.